Tag: alzheimer’s disease diagnostic market size

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Alzheimer’s Disease Diagnostic Market Growth Performance Trended Historically, And What Lies Ahead?

The market size for diagnosing Alzheimer’s disease has experienced a significant growth in recent past. It is expected to increase from a value of $6.56 billion in 2024 to $7.26 billion in 2025 with a compound annual growth rate (CAGR) of 10.7%. Factors contributing to this growth in the historic period include the rising incidence of Alzheimer’s disease and dementia, increased awareness about the significance of early diagnosis for improved management, advancements in imaging technologies such as MRI and PET scans, as well as rising investments in research and development focused on neurodegenerative diseases. Additionally, governmental initiatives and funding dedicated towards Alzheimer’s research and diagnostics have also played a role in this expansion.

In the coming years, a swift expansion is forecasted for the Alzheimer’s disease diagnostic market, with an estimation to reach $10.81 billion by 2029 with a 10.5% compound annual growth rate (CAGR). This upward trend during the forecasted period is due to the advancements in non-invasive diagnosis with blood-based biomarkers, increasing requirement for personalized medicine and precision diagnostics, integration of Artificial Intelligence and machine learning into diagnostic tools for preemptive detection, the rising adoption of digital health technologies for remote monitoring and diagnosis, as well as the developing healthcare infrastructure in emerging markets to enhance accessibility. There is an emerging trend in the forecast period of multi-modal diagnostic procedures that merge imaging, biomarkers and cognitive tests, a growing emphasis on swift results through point-of-care diagnostic solutions, development of wearable devices enabling continuous cognitive-health monitoring, greater collaborations between biotech firms and research institutions for innovative solutions, and an increase in direct-to-consumer genetic testing for Alzheimer’s risk determination.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21093&type=smp

What Are the Core Growth Drivers Propelling the Alzheimer’s Disease Diagnostic Market Forward?

The surge in chronic illnesses is anticipated to fuel the expansion of the Alzheimer’s disease diagnostic market in the future. Chronic diseases, which are health conditions that persist or last longer than three months, have seen an uptick due to a combination of various interconnected factors. These include lifestyle decisions, environmental factors, genetic predisposition, and socioeconomic conditions. Chronic conditions such as cardiovascular issues, diabetes, and hypertension heighten the risk of developing Alzheimer’s disease (AD) and other types of dementia. For example, a January 2022 report from the American Heart Association Inc., a nonprofit volunteer organization based in the U.S., predicts that brain disorders will rise to 9.3 million by 2060 in the U.S., and this figure is currently increasing. Moreover, one out of six people globally suffers from a brain disorder. It is projected that by 2021, 1 billion people worldwide will be affected by brain disorders. Consequently, the rise in chronic illnesses will fuel the expansion of the Alzheimer’s disease diagnostic market.

What Segment Types Define the Alzheimer’s Disease Diagnostic Market Structure?

The alzheimer’s disease diagnosticmarket covered in this report is segmented –

1) By Type: Triage; Diagnosis; Screening

2) By Diagnostic Technique: Biomarkers; Imaging Techniques; Genetic Testing; Cognitive Assessment Tests

3) By End User: Clinics; Hospitals; Diagnostic Centers; Pharmaceutical Companies; Academic Research Center

Subsegments:

1) By Triage: Cognitive Testing; Imaging Techniques

2) By Diagnosis: Biomarker Testing; Neuroimaging

3) By Screening: Neuropsychological Testing; Genetic Testing

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=21093&type=smp

Which Geographic Areas Hold the Strongest Growth Potential in the Alzheimer’s Disease Diagnostic Market?

North America was the largest region in the alzheimer’s disease diagnostic market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the alzheimer’s disease diagnostic market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Which Emerging Trends that Are Influencing theAlzheimer’s Disease Diagnostic Industry Evolution?

Key organizations in the Alzheimer’s disease diagnostic market are concentrating on the development of blood-based biomarker tests, a strategy anticipated to streamline the diagnostic process for Alzheimer’s, reduce dependence on more invasive methods, and enhance the availability of timely treatments for patients. For example, Quanterix, a biotechnology research firm based in the US, introduced the LucentAD p-Tau 217 test in October 2023. It serves as a biomarker presenting clinical sensitivity and specificity in blood for Alzheimer’s pathology. Classic procedures for cerebrospinal fluid (CSF) biomarkers encompass positron emission tomography (PET), or lumbar puncture, all of which prove expensive, invasive, and not easily accessible. Moreover, it synergizes Quanterix’s extremely sensitive SimoaÒ technology with p-Tau 217 antibodies tested and approved by J&J Innovative Medicine to promise excellent precision and a simplified procedure.

View the full report here:

https://www.thebusinessresearchcompany.com/report/alzheimers-disease-diagnostic-global-market-report

What Is the Definition of the Alzheimer’s Disease Diagnostic Market?

Alzheimer’s disease diagnostics encompass methods and tools used to detect and confirm the presence of Alzheimer’s disease, a progressive neurodegenerative disorder. These diagnostics include cognitive assessments, imaging techniques such as magnetic resonance imaging (MRI) and positron emission tomography (PET) scans, and biomarker tests analyzing cerebrospinal fluid (CSF) or blood for amyloid-beta and tau proteins.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21093

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Forecast for the Alzheimer’s Disease Diagnostic Market Growth in 2025?

The market size for diagnosing Alzheimer’s disease has seen substantial growth lately. It’s projected to increase from $6.56 billion in 2024 to $7.28 billion in 2025, maintaining a compound annual growth rate (CAGR) of 11%. The growth in this historic period is driven by factors such as a surge in Alzheimer’s disease and dementia cases, an increased understanding of the necessity for timely diagnosis for improved management, advancements made in imaging technologies like MRI and PET scans, a rise in investment for research and development into neurodegenerative diseases, as well as government-led initiatives and funding towards Alzheimer’s research and diagnostics.

What Is the Forecast for the Alzheimer’s Disease Diagnostic Market Size Through 2029?

The market size for Alzheimer’s disease diagnosis is predicted to witness substantial expansion in the coming years, reaching $10.91 billion by 2029 with a 10.7% compound annual growth rate (CAGR). The projected surge during this forecast period is associated with the evolution of blood-based biomarkers for non-invasive diagnostics, escalating demand for tailor-made medicine and precision diagnostics, incorporation of AI and machine learning in diagnostic equipment for precocious detection, rising utilization of digital health technology for remote monitoring and diagnosis, and upgrade of health care infrastructure in emerging markets for enhanced accessibility. Key trends expected during this period include the advent of multi-dimensional diagnostic strategies integrating imaging, biomarkers, and cognitive tests; a growing emphasis on point-of-care diagnostic procedures for quicker outcomes; the creation of wearable gadgets for perpetual monitoring of cognitive health; increasing cooperation between biotech firms and research institutions for groundbreaking solutions; and the expansion in direct-to-consumer genetic testing for Alzheimer’s risk evaluation.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21093&type=smp

What are the Key Market Players in Alzheimer’s Disease Diagnostic Market and How They’re Evolving?

Major companies operating in the alzheimer’s disease diagnostic market are Pfizer Inc., AbbVie, Bristol Myers Squibb Company, Hoffmann-La Roche, Eli Lilly and Company, Siemens Healthineers AG, Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Daiichi Sankyo Co., Sysmex, Lantheus, Quanterix, FujireBio, TauRx Pharmaceuticals Ltd, AC Immune, C2N diagnostics, AXON Neuroscience, Neuro-Bio Ltd, Anavex Life Sciences Corp., Treventis Corporation

What Are the Primary Growth Drivers in the Alzheimer’s Disease Diagnostic Market?

The surge in chronic illnesses is projected to stimulate the development of the market for Alzheimer’s disease diagnostics. Chronic illness, characterized by health conditions that persist or last for more than three months, is being fueled by an increased occurrence of a range of interlinked factors such as lifestyle decisions, environmental impacts, genetic factors, and socioeconomic conditions. Having chronic conditions like cardiovascular problems, diabetes, and high blood pressure heightens the likelihood of developing Alzheimer’s disease (AD) and other forms of dementia. For example, a report by the American Heart Association Inc., a non-profit organization based in the U.S., revealed in January 2022 that the incidence of brain disorders in the U.S. is likely to escalate to 9.3 million by 2060, and presently this number is on the rise in the U.S., with one out of every six people globally affected by a brain disease. Currently, by 2021, it is projected that 1 billion people will be affected by brain disorders globally. Consequently, the rise in chronic illnesses is likely to bolster the expansion of the market for Alzheimer’s disease diagnostics.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=21093&type=smp

What Are the Leading Segments in the Global Alzheimer’s Disease Diagnostic Industry?

The alzheimer’s disease diagnostic market covered in this report is segmented –

1) By Type: Triage, Diagnosis, Screening

2) By Diagnostic Technique: Biomarkers, Imaging Techniques, Genetic Testing, Cognitive Assessment Tests

3) By End User: Clinics, Hospitals, Diagnostic Centers, Pharmaceutical Companies, Academic Research Center

Subsegments:

1) By Triage: Cognitive Testing, Imaging Techniques

2) By Diagnosis: Biomarker Testing, Neuroimaging

3) By Screening: Neuropsychological Testing, Genetic Testing

What Are the Key Market Trends in the Alzheimer’s Disease Diagnostic Industry?

Major corporations in the diagnostic market for Alzheimer’s disease are directing their efforts towards enhancing blood-based biomarker tests, which could streamline the diagnostic procedure for Alzheimer’s disease. This progression would lessen the dependence on more invasive procedures and augment the availability of prompt treatment for patients. To illustrate, Quanterix, a biotechnology research firm from the US, launched the LucentAD p-Tau 217 test in October 2023. This test is a biomarker for Alzheimer’s pathology with clinical sensitivity and specificity in blood. Traditional cerebrospinal fluid (CSF) biomarker methods such as positron emission tomography (PET) or lumbar puncture are often expensive, invasive, and not commonly accessible. Furthermore, this test incorporates the ultra-sensitive SimoaÒ technology from Quanterix with J&J Innovative Medicine’s thoroughly examined p-Tau 217 antibodies, promising exceptional accuracy, and a simplified process.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/alzheimers-disease-diagnostic-global-market-report

What Is the Regional Outlook for the Alzheimer’s Disease Diagnostic Market?

North America was the largest region in the alzheimer’s disease diagnostic market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the alzheimer’s disease diagnostic market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21093

This Report Delivers Insight On:

1. How big is the alzheimer’s disease diagnostic market, and how is it changing globally?

2. Who are the major companies in the alzheimer’s disease diagnostic market, and how are they performing?

3. What are the key opportunities and risks in the alzheimer’s disease diagnostic market right now?

4. Which products or customer segments are growing the most in the alzheimer’s disease diagnostic market?

5. What factors are helping or slowing down the growth of the alzheimer’s disease diagnostic market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Our market reports now include the latest updates on global tariffs, trade impacts, and evolving supply chain dynamics.

What Is the Current and Projected Market Size of the Alzheimer’s Disease Diagnostic Market Through 2034?

The market size for diagnosing Alzheimer’s disease has seen a swift expansion in the recent past. From $6.56 billion in 2024, the market is projected to rise to $7.28 billion in 2025, indicating a compound annual growth rate (CAGR) of 11%. The expansion in this historic period has been spurred by factors such as a rising number of Alzheimer’s and dementia cases, growing sensitivity towards early diagnosis for improved management, advancements in imaging technologies like MRI and PET scans, increased research and development investment in neurodegenerative diseases, as well as government-led initiatives and funding dedicated to Alzheimer’s research and diagnostics.

The alzheimer’s disease diagnostic market is all set for rapid growth in the upcoming years, predicted to bolster to a whopping $10.91 billion by 2029, expanding at an impressive compound annual growth rate (CAGR) of 10.7%. This outstanding growth projection for the forecast period can be attributed to several factors such as the development of blood-based biomarkers that enable non-invasive diagnosis, a surge in demand for both personalized medicine and precision diagnostics, merging of AI and machine learning into diagnostic tools to enable early detection, an increase in the adoption of digital health technologies for diagnoses and remote monitoring, and the continued expansion of healthcare infrastructures in emerging markets to improve accessibility. Throughout the forecast period, key trends include the emergence of multi-modal diagnostic approaches that combine imaging, biomarkers, and cognitive tests, an amplified focus on point-of-care diagnostic solutions that deliver quick results, crafting of wearable devices designed for continuous cognitive health monitoring, an upward trend in collaborations between biotech companies and research institutions towards innovation, and a growing prominence in direct-to-consumer genetic testing for Alzheimer’s risk assessment.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21093&type=smp

How Are Key Drivers in the Industry Acting as Catalysts for the Growth of the Alzheimer’s Disease Diagnostic Market?

The surge in chronic illnesses is anticipated to fuel the expansion of the Alzheimer’s disease diagnostic market in the future. Chronic disease refers to a health issue that lasts more than three months. Several interconnected factors, such as lifestyle decisions, environmental factors, genetic factors, and socioeconomic conditions, contribute to this surge in chronic illnesses. The likelihood of developing Alzheimer’s disease (AD) and other types of dementia is heightened by the existence of chronic conditions like cardiovascular issues, diabetes, and hypertension. For example, the American Heart Association Inc., a volunteer organization based in the U.S., revealed in a report in January 2022 that brain disorders are projected to affect 9.3 million people in the U.S by 2060. At this time, the figure is on a rise with every sixth person around the globe suffering from a brain disease. By 2021, it is projected that 1 billion people across the globe will suffer from brain disorders. Consequently, the uptick in chronic diseases will steer the growth of the Alzheimer’s disease diagnostic market.

Which Segments in the Alzheimer’s Disease Diagnostic Offer the Most Growth?

The alzheimer’s disease diagnostic market covered in this report is segmented –

1) By Type: Triage, Diagnosis, Screening

2) By Diagnostic Technique: Biomarkers, Imaging Techniques, Genetic Testing, Cognitive Assessment Tests

3) By End User: Clinics, Hospitals, Diagnostic Centers, Pharmaceutical Companies, Academic Research Center

Subsegments:

1) By Triage: Cognitive Testing, Imaging Techniques

2) By Diagnosis: Biomarker Testing, Neuroimaging

3) By Screening: Neuropsychological Testing, Genetic Testing

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=21093&type=smp

What Are the Fastest-Growing Geographies in the #How Are Key Drivers in the Industry Acting as Catalysts for the Growth of the Alzheimer’s Disease Diagnostic Market?# Market?

North America was the largest region in the alzheimer’s disease diagnostic market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the alzheimer’s disease diagnostic market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Are the Current Market Growth and Trends in the Alzheimer’s Disease Diagnostic Industry?

Prominent firms engaged in the Alzheimer’s disease diagnostic market are emphasizing cutting-edge developments for a blood-based biomarker test that is likely to streamline Alzheimer’s disease diagnosis, lessen the dependency on more invasive methods, and enhance patient access to expedient therapy. In October 2023, Quanterix, a biotech research firm based in the US, introduced LucentAD p-Tau 217 test, a blood-based Alzheimer’s disease biomarker known for its clinical sensitivity and specificity. Traditional methods for examining cerebrospinal fluid (CSF) biomarkers, such as positron emission tomography (PET) or lumbar puncture, are expensive, invasive, and not ubiquitously available. Furthermore, this test integrates Quanterix’s highly sensitive SimoaÒ technology with J&J Innovative Medicine’s thoroughly tested p-Tau 217 antibodies, providing superb accuracy and a more streamlined process.

View the full report here:

https://www.thebusinessresearchcompany.com/report/alzheimers-disease-diagnostic-global-market-report

What Are the Key Elements That Define the Alzheimer’s Disease Diagnostic Market?

Alzheimer’s disease diagnostics encompass methods and tools used to detect and confirm the presence of Alzheimer’s disease, a progressive neurodegenerative disorder. These diagnostics include cognitive assessments, imaging techniques such as magnetic resonance imaging (MRI) and positron emission tomography (PET) scans, and biomarker tests analyzing cerebrospinal fluid (CSF) or blood for amyloid-beta and tau proteins.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21093

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

How Are Key Drivers in the Industry Acting as Catalysts for the Growth of theAlzheimer’s Disease Diagnostic Market?

Improvements in healthcare infrastructure are expected to enhance the expansion of the allergic contact dermatitis market. Healthcare infrastructure refers to the medical facilities, technologies, and resources required for providing patient care and public health services. Factors such as increased government funding, growing healthcare demand, policy changes, and private sector investments contribute to its development. Enhanced healthcare infrastructure facilitates better allergic contact dermatitis management by improving access to specialized dermatological care, supporting early diagnosis and treatment, advancing allergen research, and promoting patient education through well-equipped facilities and trained professionals. For instance, in May 2023, the American Health Care Association, a US-based nonprofit, reported that the number of hospitals in the United States had increased to 6,129, reflecting a 0.591% rise from the previous year’s 6,093. Thus, the expansion of healthcare infrastructure is positively impacting the allergic contact dermatitis market.

Get Your Free Sample Report Now – Explore Exclusive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21093&type=smp

#What Growth Opportunities Will Drive the Alzheimer’s Disease Diagnostic Market’s CAGR Through 2034?

The Alzheimer’s disease diagnostic market has experienced rapid growth. It is projected to rise from $6.56 billion in 2024 to $7.28 billion in 2025, achieving a CAGR of 11%. Contributing factors in past growth include the rising prevalence of Alzheimer’s disease and dementia, growing awareness of early diagnosis benefits, advancements in imaging technologies like MRI and PET scans, increased investments in neurodegenerative disease research, and government initiatives supporting Alzheimer’s diagnostics.

The Alzheimer’s disease diagnostic market size is anticipated to witness rapid expansion in the coming years. By 2029, it is projected to reach $10.91 billion, with a compound annual growth rate (CAGR) of 10.7%. The key factors driving this growth include the development of blood-based biomarkers for non-invasive diagnosis, increasing demand for personalized medicine and precision diagnostics, integration of AI and machine learning in diagnostic tools for early detection, growing adoption of digital health technologies for remote monitoring and diagnosis, and the expansion of healthcare infrastructure in emerging markets to improve accessibility. Significant trends in this period include the emergence of multi-modal diagnostic approaches combining imaging, biomarkers, and cognitive tests, a growing emphasis on point-of-care diagnostic solutions for faster results, development of wearable devices for continuous cognitive health monitoring, increasing collaborations between biotech companies and research institutions for innovative solutions, and growth in direct-to-consumer genetic testing for Alzheimer’s risk assessment.

You can Directly Purchase the Report Here:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21093

What Are the Current Market Growth and Trends in theAlzheimer’s Disease Diagnostic Market That Industry Players Should Watch?

In the Alzheimer’s disease diagnostic market, major companies are working on blood-based biomarker tests expected to simplify the diagnostic process for Alzheimer’s disease, reduce dependence on more invasive procedures, and improve access to timely treatment for patients. For instance, in October 2023, Quanterix, a US-based biotechnology research company, launched the LucentAD p-Tau 217 test, a blood-based biomarker for Alzheimer’s pathology with clinical sensitivity and specificity. Traditional cerebrospinal fluid (CSF) biomarker approaches, such as positron emission tomography (PET) or lumbar puncture, are costly, invasive, and not widely accessible. Quanterix’s test utilizes its ultra-sensitive SimoaÒ technology along with J&J Innovative Medicine’s p-Tau 217 antibodies to provide excellent accuracy through a simpler process.

What Are the Major Market Players Making an Impact on theAlzheimer’s Disease Diagnostic Market Growth?

Major companies operating in the alzheimer’s disease diagnostic market are Pfizer Inc., AbbVie, Bristol Myers Squibb Company, Hoffmann-La Roche, Eli Lilly and Company, Siemens Healthineers AG, Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Daiichi Sankyo Co., Sysmex, Lantheus, Quanterix, FujireBio, TauRx Pharmaceuticals Ltd, AC Immune, C2N diagnostics, AXON Neuroscience, Neuro-Bio Ltd, Anavex Life Sciences Corp., Treventis Corporation

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/alzheimers-disease-diagnostic-global-market-report

How Are the Key Segments of the Alzheimer’s Disease Diagnostic Market Driving Opportunities and Innovations?

The alzheimer’s disease diagnostic market covered in this report is segmented –

1) By Type: Triage, Diagnosis, Screening

2) By Diagnostic Technique: Biomarkers, Imaging Techniques, Genetic Testing, Cognitive Assessment Tests

3) By End User: Clinics, Hospitals, Diagnostic Centers, Pharmaceutical Companies, Academic Research Center

Subsegments:

1) By Triage: Cognitive Testing, Imaging Techniques

2) By Diagnosis: Biomarker Testing, Neuroimaging

3) By Screening: Neuropsychological Testing, Genetic Testing

Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

https://www.thebusinessresearchcompany.com/customise?id=21093&type=smp

What Regions Are At the Forefront of #How Are Key Drivers in the Industry Acting as Catalysts for the Growth of theAlzheimer’s Disease Diagnostic Market?# Market Expansion?

North America was the largest region in the alzheimer’s disease diagnostic market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the alzheimer’s disease diagnostic market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Reports Similar to the Global Alzheimer’s Disease Diagnostic Market 2025, By The Business Research Company:

Autoimmune Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/autoimmune-treatment-global-market-report

PD 1 And PDL1 Inhibitors Immune Checkpoint Inhibitors Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/pd-1-and-pdl1-inhibitors-or-immune-checkpoint-inhibitors-global-market-report

Cyclic Heavy Menstrual Bleeding Global Market Report 2025

https://thebusinessresearchcompany.com/report/cyclic-heavy-menstrual-bleeding-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.

How has the alzheimer’s disease diagnostic market size evolved in recent years?

In the past few years, there has been a swift expansion in the market size of Alzheimer’s disease diagnosis. The market worth, which stands at $6.56 billion in 2024, is projected to escalate to $7.28 billion in 2025, following a consistent compound annual growth rate (CAGR) of 11%. This historical augmentation can be credited to a heightened incidence of Alzheimer’s disease and dementia, mounting cognizance of the significance of pre-emptive diagnosis for superior disease management, advancements in imaging technologies like MRI and PET scans. There is also an upsurge in investment in the research and development sector related to neurodegenerative diseases along with government initiatives and funding aimed at Alzheimer’s research and diagnostic procedures.

What are the predictions for the alzheimer’s disease diagnostic market size in the coming years?

Over the next several years, the diagnostic market for Alzheimer’s disease is projected to experience significant growth, with it expanding to $10.91 billion in 2029 and a compound annual growth rate (CAGR) of 10.7%. This forecasted growth can be linked to the creation of blood-based biomarkers for non-invasive diagnosis, increasing demand for personalized and precision medicine, the use of AI and machine learning in early detection tools, the increased uptake of digital healthcare technology for remote diagnosis and monitoring, and improvements in healthcare infrastructure in emerging markets for better accessibility. Major trends anticipated during this forecast period include the rising use of multi-modal diagnostic techniques which combines imaging, biomarkers and cognitive tests, a growing emphasis on point-of-care diagnostic solutions for quicker outcomes, the creation of wearable devices that offer continuous monitoring of cognitive health, growing partnerships between biotech firms and research institutions for innovative solutions, and an increase in direct-to-consumer genetic testing for Alzheimer’s risk evaluation.

Get your alzheimer’s disease diagnostic market report here!

https://www.thebusinessresearchcompany.com/report/alzheimers-disease-diagnostic-global-market-report

What key factors are fueling the growth of the alzheimer’s disease diagnostic market?

The surge in chronic illnesses is likely to stimulate the expansion of the alzheimer’s disease diagnostic market. Chronic disease refers to any health issue that lasts for over three months. The escalation in chronic diseases is attributed to several interconnected factors including lifestyle choices, environmental factors, genetic predisposition, and socioeconomic conditions. Possessing chronic conditions like cardiovascular issues, diabetes, and high blood pressure heightens the risk of developing Alzheimer’s disease and other types of dementia. For example, a report released by the American Heart Association Inc., a US-based volunteer organization, in January 2022 indicated that brain disorders are projected to rise to 9.3 million in the US by 2060. At present, this number is on the rise in the US, and globally, one in every six people suffers from a brain disease. By 2021, it is anticipated that 1 billion individuals globally will be suffering from brain disorders. Thus, the surge in chronic diseases is predicted to fuel the growth of the alzheimer’s disease diagnostic market.

How is the global alzheimer’s disease diagnostic market divided into key segments?

The alzheimer’s disease diagnostic market covered in this report is segmented –

1) By Type: Triage, Diagnosis, Screening

2) By Diagnostic Technique: Biomarkers, Imaging Techniques, Genetic Testing, Cognitive Assessment Tests

3) By End User: Clinics, Hospitals, Diagnostic Centers, Pharmaceutical Companies, Academic Research Center

Subsegments:

1) By Triage: Cognitive Testing, Imaging Techniques

2) By Diagnosis: Biomarker Testing, Neuroimaging

3) By Screening: Neuropsychological Testing, Genetic Testing

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21093&type=smp

Who are the key firms paving the way for growth in the alzheimer’s disease diagnostic market?

Major companies operating in the alzheimer’s disease diagnostic market are Pfizer Inc., AbbVie, Bristol Myers Squibb Company, Hoffmann-La Roche, Eli Lilly and Company, Siemens Healthineers AG, Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Daiichi Sankyo Co., Sysmex, Lantheus, Quanterix, FujireBio, TauRx Pharmaceuticals Ltd, AC Immune, C2N diagnostics, AXON Neuroscience, Neuro-Bio Ltd, Anavex Life Sciences Corp., Treventis Corporation

What emerging trends are influencing the growth of the alzheimer’s disease diagnostic market?

Leading organizations in the Alzheimer’s disease diagnostic market are centering their efforts on the progression of blood-based biomarker tests. These advancements aim to streamline the diagnosis procedure for Alzheimer’s disease, decreasing the necessity for more invasive procedures and enhancing patients’ ability to access treatment promptly. In an exemplification of this, Quanterix – a biotechnology research entity based in the US, unveiled the LucentAD p-Tau 217 test in October 2023. This serves as a biomarker for Alzheimer’s pathology that exhibits clinical sensitivity and specificity in blood. Traditional methods for detecting cerebrospinal fluid (CSF) biomarkers, such as positron emission tomography (PET) or lumbar puncture, are not only expensive and invasive but also limited in availability. However, Quanterix’s ultra-sensitive SimoaÒ technology merges with J&J Innovative Medicine’s thoroughly examined p-Tau 217 antibodies, creating an exceedingly accurate solution that simplifies the process.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21093

What regions are contributing significantly to the growth of the alzheimer’s disease diagnostic market?

North America was the largest region in the alzheimer’s disease diagnostic market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the alzheimer’s disease diagnostic market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Autoimmune Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/autoimmune-treatment-global-market-report

PD 1 And PDL1 Inhibitors Immune Checkpoint Inhibitors Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/pd-1-and-pdl1-inhibitors-or-immune-checkpoint-inhibitors-global-market-report

Cyclic Heavy Menstrual Bleeding Global Market Report 2025

https://thebusinessresearchcompany.com/report/cyclic-heavy-menstrual-bleeding-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What is the Growth Potential of the Alzheimer’s Disease Diagnostic Market, and How Will It Perform by 2034?

The market size for Alzheimer’s disease diagnostics has been expanding swiftly in the past years. From being worth $6.56 billion in 2024, it is expected to swell to $7.28 billion by 2025 with a compound annual growth rate (CAGR) of 11%. The impressive growth during the historical period is due to an increased number of Alzheimer’s disease and dementia cases, heightened awareness about the necessity of timely diagnosis for efficient management, progress in imaging technologies like MRI and PET scans, more funds being allocated for research and development in the domain of neurodegenerative diseases, and government-led initiatives and financial support for research and diagnostic processes associated with Alzheimer’s.

Rapid expansion is anticipated in the Alzheimer’s disease diagnostic market size in the coming years, with its worth predicted to reach $10.91 billion by 2029, progressing at a compound annual growth rate (CAGR) of 10.7%. This surge over the projected period can be ascribed to factors such as the evolution of non-invasive diagnosis through blood-based biomarkers, the escalating requirement for personalized medicine and precision diagnostics, incorporation of AI and machine learning into diagnostic instruments for early detection, augmented uptake of digital health technologies for remote supervision and diagnosis, and the broadening of healthcare infrastructure in growing markets to boost accessibility. Notable trends in the prediction time frame include the development of multi-modal diagnostic tactics that merge imaging, biomarkers, and cognitive examinations, a heightened emphasis on rapid result point-of-care diagnostic solutions, the creation of wearable technology for constant cognitive health monitoring, increasing partnerships between biotech firms and research enterprises for inventive solutions, and growth in direct-to-consumer genetic testing for evaluating Alzheimer’s risk.

How Are the key drivers Contributing to the Expansion of the Alzheimer’s Disease Diagnostic Market?

Forecasted growth in the alzheimer’s disease diagnostic market is attributed to the anticipated rise in chronic illnesses, conditions which persist for over three months. This escalation in chronic illness is linked to numerous interrelated factors, including lifestyle decisions, environmental impacts, genetic factors, and soci-economic standing. Chronic health issues like heart disease, diabetes, and hypertension enhance vulnerability to Alzheimer’s disease (AD) and other dementia types. As per a report from the American Heart Association Inc., a US-based nonprofit volunteer organization, in January 2022, it’s projected that brain disorders in the US will rise to 9.3 million by 2060, a figure that’s currently on the increase, with one in six people worldwide affected by a brain disease. It’s estimated that by the end of 2021, 1 billion people worldwide will be dealing with brain disorders. Consequently, the surge in chronic illnesses is likely to stimulate the alzheimer’s disease diagnostic market’s growth.

Request Your Free Alzheimer’s Disease Diagnostic Market Report Sample Now!

https://www.thebusinessresearchcompany.com/sample.aspx?id=21093&type=smp

Who Are the Major Companies Shaping the Competitive Landscape of the Alzheimer’s Disease Diagnostic Market?

Major companies operating in the alzheimer’s disease diagnostic market are Pfizer Inc., AbbVie, Bristol Myers Squibb Company, Hoffmann-La Roche, Eli Lilly and Company, Siemens Healthineers AG, Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Daiichi Sankyo Co., Sysmex, Lantheus, Quanterix, FujireBio, TauRx Pharmaceuticals Ltd, AC Immune, C2N diagnostics, AXON Neuroscience, Neuro-Bio Ltd, Anavex Life Sciences Corp., Treventis Corporation

What Are the Key Emerging Trends in the Alzheimer’s Disease Diagnostic Market for the Next Decade?

Leading entities in the Alzheimer’s disease diagnostic market are centering their efforts on enhancing the development of blood-based biomarker tests. This advancement promises to simplify the diagnosis process for Alzheimer’s disease, lessen dependency on more invasive methods, and amplify access to prompt treatment for patients. Quanterix, an American biotechnology research firm, introduced the LucentAD p-Tau 217 test, an Alzheimer’s pathology biomarker noted for its clinical sensitivity and specificity in blood, in October 2023. Conventionally, cerebrospinal fluid (CSF) biomarkers leaned heavily on positron emission tomography (PET) or lumbar puncture, both of which are expensive, invasive and not extensively accessible. Moreover, the firm merges its super-sensitive SimoaÒ technology with J&J Innovative Medicine’s thoroughly examined p-Tau 217 antibodies, resulting in remarkable accuracy and a streamlined process.

Pre-order Your Report for Quick and Easy Delivery!

https://www.thebusinessresearchcompany.com/report/alzheimers-disease-diagnostic-global-market-report

What Are the Core Categories and Segments in the Alzheimer’s Disease Diagnostic Market Driving Demand and Growth?

The alzheimer’s disease diagnostic market covered in this report is segmented –

1) By Type: Triage, Diagnosis, Screening

2) By Diagnostic Technique: Biomarkers, Imaging Techniques, Genetic Testing, Cognitive Assessment Tests

3) By End User: Clinics, Hospitals, Diagnostic Centers, Pharmaceutical Companies, Academic Research Center

Subsegments:

1) By Triage: Cognitive Testing, Imaging Techniques

2) By Diagnosis: Biomarker Testing, Neuroimaging

3) By Screening: Neuropsychological Testing, Genetic Testing

Which Regions Are Making a Mark in the Alzheimer’s Disease Diagnostic Market Growth?

North America was the largest region in the alzheimer’s disease diagnostic market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the alzheimer’s disease diagnostic market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

How Is the Alzheimer’s Disease Diagnostic Market Categorized and Defined in the Industry?

Alzheimer’s disease diagnostics encompass methods and tools used to detect and confirm the presence of Alzheimer’s disease, a progressive neurodegenerative disorder. These diagnostics include cognitive assessments, imaging techniques such as magnetic resonance imaging (MRI) and positron emission tomography (PET) scans, and biomarker tests analyzing cerebrospinal fluid (CSF) or blood for amyloid-beta and tau proteins.

Browse Through More Similar Reports By The Business Research Company:

Autoimmune Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/autoimmune-treatment-global-market-report

PD 1 And PDL1 Inhibitors Immune Checkpoint Inhibitors Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/pd-1-and-pdl1-inhibitors-or-immune-checkpoint-inhibitors-global-market-report

Cyclic Heavy Menstrual Bleeding Global Market Report 2025

https://thebusinessresearchcompany.com/report/cyclic-heavy-menstrual-bleeding-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: